A komplementrendszer terapias manipulaciojanak lehetosegei

Translated title of the contribution: Possibilities for the therapeutic manipulation of the plasma complement system

G. Füst, L. Varga

Research output: Contribution to journalArticle

Abstract

Authors summarize the results and perspectives of therapeutic complement inhibition aiming to suppress the activation of an important effector mechanism of the immunity, the serum complement system. It seems most probable that complement suppression therapy will be used in the clinical practice in the near future. According to some recent findings, widespread used drugs like heparin or intravenous immunoglobulin act at least partly through the inhibition of complement activation. Other drugs were developed with aim to suppress the complement system. Therapeutic trials are already in progress with some of these drugs and a constant increase of the phase I, phase II and even phase III trials with these drugs is expected. In the first part the structure, biochemical function, activation pathways of the complement system as well as the biologically active and pathologically important fragments of the complement proteins are shortly described. Then observations obtained in patients and findings of animal experiments supporting the essential role of complement activation in the pathomechanism of several human diseases are summarized. Since most of these diseases are frequent and severe, it seemed worthwhile to develop drugs for suppressing complement activation and thus influencing the course of these diseases in favorable direction. The potential dangers of the complement inhibition therapy are also detailed. In the second part of the review, groups of drugs suitable for the complement inhibition therapy and the most important results achieved with these drugs are summarized.

Original languageHungarian
Pages (from-to)348-355
Number of pages8
JournalLege Artis Medicinae
Volume9
Issue number5
Publication statusPublished - 1999

Fingerprint

Complement Activation
Pharmaceutical Preparations
Therapeutics
Intravenous Immunoglobulins
Heparin
Immunity
Complement System Proteins
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A komplementrendszer terapias manipulaciojanak lehetosegei. / Füst, G.; Varga, L.

In: Lege Artis Medicinae, Vol. 9, No. 5, 1999, p. 348-355.

Research output: Contribution to journalArticle

@article{1405b88b90d845e4bee50c96000fec3e,
title = "A komplementrendszer terapias manipulaciojanak lehetosegei",
abstract = "Authors summarize the results and perspectives of therapeutic complement inhibition aiming to suppress the activation of an important effector mechanism of the immunity, the serum complement system. It seems most probable that complement suppression therapy will be used in the clinical practice in the near future. According to some recent findings, widespread used drugs like heparin or intravenous immunoglobulin act at least partly through the inhibition of complement activation. Other drugs were developed with aim to suppress the complement system. Therapeutic trials are already in progress with some of these drugs and a constant increase of the phase I, phase II and even phase III trials with these drugs is expected. In the first part the structure, biochemical function, activation pathways of the complement system as well as the biologically active and pathologically important fragments of the complement proteins are shortly described. Then observations obtained in patients and findings of animal experiments supporting the essential role of complement activation in the pathomechanism of several human diseases are summarized. Since most of these diseases are frequent and severe, it seemed worthwhile to develop drugs for suppressing complement activation and thus influencing the course of these diseases in favorable direction. The potential dangers of the complement inhibition therapy are also detailed. In the second part of the review, groups of drugs suitable for the complement inhibition therapy and the most important results achieved with these drugs are summarized.",
keywords = "C1 inhibitor, C5a, Complement, Complement activation, Complement inhibition therapy, CR1",
author = "G. F{\"u}st and L. Varga",
year = "1999",
language = "Hungarian",
volume = "9",
pages = "348--355",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "5",

}

TY - JOUR

T1 - A komplementrendszer terapias manipulaciojanak lehetosegei

AU - Füst, G.

AU - Varga, L.

PY - 1999

Y1 - 1999

N2 - Authors summarize the results and perspectives of therapeutic complement inhibition aiming to suppress the activation of an important effector mechanism of the immunity, the serum complement system. It seems most probable that complement suppression therapy will be used in the clinical practice in the near future. According to some recent findings, widespread used drugs like heparin or intravenous immunoglobulin act at least partly through the inhibition of complement activation. Other drugs were developed with aim to suppress the complement system. Therapeutic trials are already in progress with some of these drugs and a constant increase of the phase I, phase II and even phase III trials with these drugs is expected. In the first part the structure, biochemical function, activation pathways of the complement system as well as the biologically active and pathologically important fragments of the complement proteins are shortly described. Then observations obtained in patients and findings of animal experiments supporting the essential role of complement activation in the pathomechanism of several human diseases are summarized. Since most of these diseases are frequent and severe, it seemed worthwhile to develop drugs for suppressing complement activation and thus influencing the course of these diseases in favorable direction. The potential dangers of the complement inhibition therapy are also detailed. In the second part of the review, groups of drugs suitable for the complement inhibition therapy and the most important results achieved with these drugs are summarized.

AB - Authors summarize the results and perspectives of therapeutic complement inhibition aiming to suppress the activation of an important effector mechanism of the immunity, the serum complement system. It seems most probable that complement suppression therapy will be used in the clinical practice in the near future. According to some recent findings, widespread used drugs like heparin or intravenous immunoglobulin act at least partly through the inhibition of complement activation. Other drugs were developed with aim to suppress the complement system. Therapeutic trials are already in progress with some of these drugs and a constant increase of the phase I, phase II and even phase III trials with these drugs is expected. In the first part the structure, biochemical function, activation pathways of the complement system as well as the biologically active and pathologically important fragments of the complement proteins are shortly described. Then observations obtained in patients and findings of animal experiments supporting the essential role of complement activation in the pathomechanism of several human diseases are summarized. Since most of these diseases are frequent and severe, it seemed worthwhile to develop drugs for suppressing complement activation and thus influencing the course of these diseases in favorable direction. The potential dangers of the complement inhibition therapy are also detailed. In the second part of the review, groups of drugs suitable for the complement inhibition therapy and the most important results achieved with these drugs are summarized.

KW - C1 inhibitor

KW - C5a

KW - Complement

KW - Complement activation

KW - Complement inhibition therapy

KW - CR1

UR - http://www.scopus.com/inward/record.url?scp=0032981832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032981832&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032981832

VL - 9

SP - 348

EP - 355

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 5

ER -